中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1057-1062.doi: 10.35541/cjd.20210568
中华医学会皮肤性病学分会荨麻疹研究中心
收稿日期:
2021-08-06
修回日期:
2021-09-26
发布日期:
2021-12-01
通讯作者:
徐金华
E-mail:xjhhsyy@163.com
Centre for Urticaria Research, Chinese Society of Dermatology
Received:
2021-08-06
Revised:
2021-09-26
Published:
2021-12-01
Contact:
Xu Jinhua
E-mail:xjhhsyy@163.com
摘要: 【摘要】 慢性荨麻疹是一种常见的免疫相关性皮肤病,具有反复发作、迁延不愈等特点,部分患者对常规抗组胺药物治疗效果不佳,生活质量受到严重影响。目前,国内外多项研究证实,一类以新型生物制剂为主的抗IgE疗法能够较为有效和安全地应用于慢性荨麻疹等疾病的治疗。为规范并促进临床医生对抗IgE疗法的应用和认识,基于国外指南及近年相关研究报道,中华医学会皮肤性病学分会荨麻疹研究中心组织有关专家制订本共识,以奥马珠单抗为代表,详细介绍抗IgE疗法治疗慢性荨麻疹的具体机制、应用方案和注意事项,为皮肤科医务工作者提供相关的理论依据和用药指导。
中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识[J]. 中华皮肤科杂志, 2021,54(12):1057-1062. doi:10.35541/cjd.20210568
Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy (omalizumab)[J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062.doi:10.35541/cjd.20210568
[1] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1): 1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[2] | Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update[J]. J Allergy Clin Immunol, 2014,133(5):1270⁃1277. doi: 10.1016/j.jaci.2014.02.036. |
[3] | Ulambayar B, Park HS. Anti⁃TPO IgE autoantibody in chronic urticaria: is it clinically relevant?[J]. Allergy Asthma Immunol Res, 2019,11(1):1⁃3. doi: 10.4168/aair.2019.11.1.1. |
[4] | Kaplan AP, Giménez⁃Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria[J]. Allergy, 2017,72(4):519⁃533. doi: 10.1111/all.13 083. |
[5] | Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin[J]. Theranostics, 2017,7(5):1266⁃1276. doi: 10.7150/thno.18304. |
[6] | Serrano⁃Candelas E, Martinez⁃Aranguren R, Valero A, et al. Comparable actions of omalizumab on mast cells and basophils[J]. Clin Exp Allergy, 2016,46(1):92⁃102. doi: 10.1111/cea. 12668. |
[7] | Chan MA, Gigliotti NM, Dotson AL, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells[J]. Clin Transl Allergy, 2013,3(1):29. doi: 10.1186/2045⁃7022⁃3⁃29. |
[8] | Sánchez⁃Machín I, Iglesias⁃Souto J, Franco A, et al. T cell activity in successful treatment of chronic urticaria with omalizumab[J]. Clin Mol Allergy, 2011,9:11. doi: 10.1186/1476⁃7961⁃9⁃11. |
[9] | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
[10] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa121 5372. |
[11] | Saini SS, Bindslev⁃Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo⁃controlled study[J]. J Invest Dermatol, 2015,135(1):67⁃75. doi: 10.1038/jid.2014.306. |
[12] | Novartis Pharmaceuticals. Study of efficacy and safety of Xolair® (Omalizumab) in Chinese patients with chronic spontaneous urticaria[DB/OL]. (2020⁃11⁃04)[2021⁃10⁃08]. https://clinicaltrials.gov/ct2/show/NCT03328897. |
[13] | 张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021,54(7):582⁃585. doi: 10.35541/cjd.20201261. |
[14] | Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043. |
[15] | Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042. |
[16] | Gastaminza G, Azofra J, Nunez⁃Cordoba JM, et al. Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double⁃blind and open⁃label placebo⁃controlled clinical trial[J]. J Allergy Clin Immunol Pract, 2019,7(5):1599⁃1609.e1. doi: 10.1016/j.jaip.2018.12.025. |
[17] | Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032. |
[18] | Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria[J]. Ann Allergy Asthma Immunol, 2015,115(2):126⁃129. doi: 10.1016/j.anai. 2015.05.010. |
[19] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[20] | Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence⁃based practice guidelines for chronic spontaneous urticaria in Korean adults and children: Part 2. Management of H1⁃antihistamine⁃refractory chronic urticaria[J]. Allergy Asthma Immunol Res, 2020,12(5):750⁃770. doi: 10.4168/aair.2020.12. 5.750. |
[21] | Cox L, Platts⁃Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/american College of Allergy, Asthma And Immunology Joint Task Force Report on omalizumab⁃associated anaphylaxis[J]. J Allergy Clin Immunol, 2007,120(6):1373⁃1377. doi: 10.1016/j.jaci.2007.09.032. |
[22] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[23] | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091. |
[24] | Curto⁃Barredo L, Spertino J, Figueras⁃Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria[J]. Br J Dermatol, 2018,179(1):210⁃212. doi: 10.1111/bjd.16379. |
[25] | Serarslan G, Uzun M, Doğramacı AÇ, et al. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study[J]. Dermatol Ther, 2019,32(1):e12752. doi: 10.1111/dth.12752. |
[26] | Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345. |
[27] | Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(5):918⁃924. doi: 10.1111/jdv.15350. |
[28] | Ferrer M, Boccon⁃Gibod I, Gonçalo M, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria[J]. Eur J Dermatol, 2017,27(5):455⁃463. doi: 10.1684/ejd.2017.3085. |
[29] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[30] | Pinto Gouveia M, Gameiro A, Pinho A, et al. Long⁃term management of chronic spontaneous urticaria with omalizumab[J]. Clin Exp Dermatol, 2017,42(7):735⁃742. doi: 10.1111/ced. 13173. |
[31] | Alizadeh Aghdam M, Pieterse RH, Kentie PA, et al. Effective omalizumab interval prolongation in the treatment of chronic urticaria[J]. J Allergy Clin Immunol Pract, 2020,8(10):3667⁃3668.e1. doi: 10.1016/j.jaip.2020.06.056. |
[32] | Kavati A, Zhdanava M, Ortiz B, et al. Long⁃term omalizumab outcomes in chronic idiopathic urticaria: a real⁃world study[J]. Allergy Asthma Proc, 2019,40(5):321⁃328. doi: 10.2500/aap. 2019.40.4236. |
[33] | Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ′real⁃world′ evidence[J]. Expert Opin Biol Ther, 2018,18(4):425⁃448. doi: 10.1080/14712598.2018.1438406. |
[34] | 奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018,41(3):179⁃185. doi: 10.3760/cma.j.issn.1001⁃0939.2018.03.007. |
[35] | Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies[J]. Case Rep Med, 2015,2015:368053. doi: 10.1155/2015/368053. |
[36] | Ben⁃Shoshan M, Grattan CE. Management of pediatric urticaria with review of the literature on chronic spontaneous urticaria in children[J]. J Allergy Clin Immunol Pract, 2018,6(4):1152⁃1161. doi: 10.1016/j.jaip.2018.02.015. |
[37] | Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers[J]. J Allergy Clin Immunol Pract, 2020,8(1):113⁃124. doi: 10.1016/j.jaip.2019.07.021. |
[38] | Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real⁃life experience[J]. Ann Allergy Asthma Immunol, 2018,120(3):318⁃323. doi: 10.1016/j.anai.2017.12.007. |
[39] | Agache I, Akdis C, Akdis M, et al. EAACI Biologicals Guidelines⁃Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12⁃17 years old[J/OL]. Allergy, 2021 (2021⁃07⁃29) [2021⁃10⁃08]. https://onlinelibrary.wiley.com/doi/10.1111/all.15030. doi: 10. 1111/ all.15030. [published online ahead of print]. |
[40] | Martina E, Damiani G, Grieco T, et al. It is never too late to treat chronic spontaneous urticaria with omalizumab: real⁃life data from a multicenter observational study focusing on elderly patients[J]. Dermatol Ther, 2021,34(2):e14841. doi: 10.1111/dth.14841. |
[41] | Bauer A, Dickel H, Jakob T, et al. Expert consensus on practical aspects in the treatment of chronic urticaria[J]. Allergo J Int, 2021,30(2):64⁃75. doi: 10.1007/s40629⁃021⁃00162⁃w. |
[42] | Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria[J]. N Engl J Med, 2019,381(14):1321⁃1332. doi: 10.1056/NEJMoa1900408. |
[43] | Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria[J]. J Allergy Clin Immunol, 2016, 138(6):1730⁃1732. doi: 10.1016/j.jaci.2016.06.023. |
[1] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
[2] | 李浩, 王俐 韩宪伟 孙彤 苏芳 孙晓冬 韩莹 杨国玲 刘晓明 王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218. |
[3] | 王娟娟 陈容 季江 苏文星 魏钰倩 赵莹 尹兴平 苏玉华 施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234. |
[4] | 王晓雯 李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275. |
[5] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
[6] | 张婷婷 朱凤仪 杨梅 张平 夏萍 周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644. |
[7] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
[8] | 陆佳维, 鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210420-e20210420. |
[9] | 高蓉 张兰 李政霄. 生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展[J]. 中华皮肤科杂志, 2022, 55(1): 72-75. |
[10] | 郭静 杨景煜 丁黎 刘明明 侯晶梅 蒲小霞 孙嘉昱 李向花. 长脉宽1 064 nm Nd:YAG激光联合含滇山茶和三七等提取物的外用乳剂治疗黄褐斑的疗效[J]. 中华皮肤科杂志, 2022, 55(1): 61-64. |
[11] | 郭伟 赵涛 郭伟楠 马翠玲 高天文 赵建红 李冰. 早期甲黑素瘤115例手术治疗方案和预后回顾分析[J]. 中华皮肤科杂志, 2021, 54(9): 777-784. |
[12] | 虞英媛 李影 余增洋 郑建锋 张希琳 丁杨峰 史玉玲. 英夫利西单抗治疗重度斑块状银屑病的疗效和安全性及其对PD-1、PD-L1表达的影响[J]. 中华皮肤科杂志, 2021, 54(7): 590-596. |
[13] | 张宇 高迎霞 顾宁琰 朱虹 陈京京 胡清洁 周敏 段媛媛 姚煦. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585. |
[14] | 梁高澎 宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556. |
[15] | 罗帅寒天 龙海 陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545. |
|